Literature DB >> 21189339

Interaction potential of etravirine with drug transporters assessed in vitro.

Nadine Cécile Luise Zembruski1, Walter Emil Haefeli, Johanna Weiss.   

Abstract

Etravirine is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infections. ABC transporters potentially mediate clinically relevant drug-drug interactions. We assessed substrate characteristics and the inhibitory and inductive potential of etravirine on ABC transporters. Etravirine did not inhibit P-gp/ABCB1 and was not transported by the tested ABC transporters but was a potent inhibitor of BCRP/ABCG2. Etravirine induced several ABC transporters, especially BCRP/ABCG2. These data demonstrate that etravirine has the potential for drug-drug interactions by modulation of expression and function of several ABC transporters.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21189339      PMCID: PMC3067076          DOI: 10.1128/AAC.01527-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

Authors:  M T Huisman; J W Smit; A H Schinkel
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

2.  Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

Authors:  J Mallolas; M Sarasa; M Nomdedeu; A Soriano; Y López-Púa; J L Blanco; E Martínez; J M Gatell
Journal:  HIV Med       Date:  2007-03       Impact factor: 3.180

3.  Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.

Authors:  Yaming Su; Xiaoping Zhang; Patrick J Sinko
Journal:  Mol Pharm       Date:  2004-01-12       Impact factor: 4.939

4.  TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1.

Authors:  R Evers; N H Cnubben; J Wijnholds; L van Deemter; P J van Bladeren; P Borst
Journal:  FEBS Lett       Date:  1997-12-08       Impact factor: 4.124

6.  Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.

Authors:  Nadine Cécile Luise Zembruski; Gabriele Büchel; Lisa Jödicke; Melanie Herzog; Walter Emil Haefeli; Johanna Weiss
Journal:  J Antimicrob Chemother       Date:  2011-01-19       Impact factor: 5.790

7.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.

Authors:  R Evers; M Kool; L van Deemter; H Janssen; J Calafat; L C Oomen; C C Paulusma; R P Oude Elferink; F Baas; A H Schinkel; P Borst
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

8.  Inhibition of P-glycoprotein by newer antidepressants.

Authors:  Johanna Weiss; Sven-Maria Gregor Dormann; Meret Martin-Facklam; Christian Johannes Kerpen; Nahal Ketabi-Kiyanvash; Walter Emil Haefeli
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

9.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

Authors:  Maarten T Huisman; Johan W Smit; Kristel M L Crommentuyn; Noam Zelcer; Hugh R Wiltshire; Jos H Beijnen; Alfred H Schinkel
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

10.  Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.

Authors:  Petr Pavek; Gracia Merino; Els Wagenaar; Ellen Bolscher; Martina Novotna; Johan W Jonker; Alfred H Schinkel
Journal:  J Pharmacol Exp Ther       Date:  2004-09-13       Impact factor: 4.030

View more
  8 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 2.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

Review 3.  Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.

Authors:  B Ryan Phelps; Natella Rakhmanina
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

4.  Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.

Authors:  Manoli Vourvahis; Anna Plotka; Laure Mendes da Costa; Annie Fang; Jayvant Heera
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review.

Authors:  Joshua P Havens; Anthony T Podany; Kimberly K Scarsi; Courtney V Fletcher
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

6.  Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.

Authors:  Gabriel Kigen; Geoffrey Edwards
Journal:  BMC Pharmacol Toxicol       Date:  2017-05-04       Impact factor: 2.483

7.  Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices.

Authors:  Martin Huličiak; Ivan Vokřál; Ondřej Holas; Ondřej Martinec; František Štaud; Lukáš Červený
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-18

8.  Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.

Authors:  Sanna R Rijpma; Jeroen J M W van den Heuvel; Maarten van der Velden; Robert W Sauerwein; Frans G M Russel; Jan B Koenderink
Journal:  Malar J       Date:  2014-09-13       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.